Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.930
-0.080 (-3.98%)
Jun 13, 2025, 4:00 PM - Market closed
Heron Therapeutics Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Heron Therapeutics stock ranges from a low of $4.00 to a high of $6.00. The average analyst price target of $5.00 forecasts a 159.07% increase in the stock price over the next year.
Price Target: $5.00 (+159.07%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Heron Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +210.88% | Jun 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +107.25% | Apr 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +107.25% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +107.25% | Dec 4, 2024 |
| Needham | Needham | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +107.25% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
162.47M
from 144.29M
Increased by 12.60%
Revenue Next Year
184.67M
from 162.47M
Increased by 13.66%
EPS This Year
-0.03
from -0.09
EPS Next Year
0.08
from -0.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 167.9M | 192.9M | 211.8M | ||
| Avg | 162.5M | 184.7M | 205.0M | ||
| Low | 155.0M | 174.8M | 196.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.4% | 18.7% | 14.7% | ||
| Avg | 12.6% | 13.7% | 11.0% | ||
| Low | 7.4% | 7.6% | 6.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 0.12 | 0.27 | ||
| Avg | -0.03 | 0.08 | 0.21 | ||
| Low | -0.06 | 0.05 | 0.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 234.6% | ||
| Avg | - | - | 156.2% | ||
| Low | - | - | 80.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.